GRAIL (GRAL) Stock Price, Quote, News & History | Benzinga

SPY769.62−0.00%QQQ749.60+0.00%BTC/USD84,443.39−0.48%DIA511.21+0.02%GLD379.64−0.13%TLT77.53+0.06%

GRAIL Inc (GRAL) Stock Price, Quote, News & History

GRALNASDAQ

Trade with Public

Trade with Public

$143.26

10.708.07%

Last update: Oct 2, 4:05 PM

$143.75

11.198.44%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$135.52

Close

$143.26

Volume / Avg.

872.23K / 887.26K

Day Range

$134.45 - $143.50

52 Wk Range

41.50 - 151.46

Market Cap

$6.42B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

82

Short Interest

19.48%

Days to Cover

12.66

Recent Grail Inc News

FDA Panel Endorses GRAIL Galleri Cancer Screening Tool

The FDA advisory committee voted in favor of GRAIL's Galleri multi-cancer early detection test, moving it closer to official approval.

Vandana Singh

Low False Positives and High Accuracy: FDA Document Fueling Grail Stock Surge

Grail stock surges on favorable FDA briefing documents back its Galleri multi-cancer test ahead of the September 23 advisory committee vote.

Vandana Singh

Critical Metals, Priority Technology, Meta Platforms And Other Big Stocks Moving Higher On Monday

U.S. stocks rose Monday, with Nasdaq up 1%. Critical Metals jumped 38% on Greenland deal news as tech and other shares broadly gained.

Avi Kapoor

Grail Analyst Sees Massive Market Potential with Valuation Headwinds

Grail "is a pure play," according to RBC Capital Markets. The company offers a tool for screening malignancies that lack standard protocols.

Vandana Singh

FDA Panel Schedules to Evaluate GRAIL Premarket Approval Application for Multi-Cancer Early Detection Test

The FDA's advisory committee will meet on September 23 to review the PMA application for GRAIL's Galleri multi-cancer early detection test.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-294.75M

Investing Cash Flow (TTM)

-310.04M

Financing Cash Flow (TTM)

536.93M

Free Cash Flow (TTM)

-296.16M

Capital Expenditure (TTM)

-1.41M

Net Change in Cash (TTM)

-67.86M

Analyst Trends and Forecast

1

Jun

1

Jul

3

1

Sep

2

Oct

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.0

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$5.15B

PE Ratio (TTM)

-

PE Ratio (FWD)

1.27

PEG Ratio (TTM)

-

PS Ratio (TTM)

32.22

PB Ratio (TTM)

2.33

Earnings Yield % (TTM)

-7.31%

Earnings Yield % (FWD)

78.58%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$56.93

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$55.65M

Debt to Equity

0.04

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-